Collier B D, Adams M B, Kauffman H M, Trembath L, Hoffmann R G, Tisdale P L, Rao S A, Hellman R S, Isitman A T
Department of Radiology, Froedtert Memorial Lutheran Hospital, Medical College of Wisconsin, Milwaukee.
Clin Nucl Med. 1988 Aug;13(8):606-10. doi: 10.1097/00003072-198808000-00014.
Previous reports indicate that In-111 platelet scintigraphy (IPS) is a reliable test for the early diagnosis of acute post-operative renal transplant rejection (TR). However, the recent introduction of cyclosporin for post-transplantation immunosuppression requires that the diagnostic efficacy of IPS once again be established. Therefore, a prospective IPS study of 73 post-operative renal transplant recipients was conducted. Fourty-nine patients received cyclosporin and 24 patients did not receive this drug. Between these two patient groups, there were no significant differences in the diagnostic sensitivities (0.86 vs 0.80) and specificities (0.93 vs 0.84) with which TR was identified. We conclude that during the first two weeks following renal transplantation the cyclosporin treatment regimen used at our institution does not limit the reliability of IPS as a test for TR.
先前的报告表明，铟-111血小板闪烁显像（IPS）是术后早期诊断急性肾移植排斥反应（TR）的可靠检测方法。然而，近期环孢素被用于移植后免疫抑制，这就需要再次确定IPS的诊断效能。因此，我们对73例术后肾移植受者进行了一项前瞻性IPS研究。49例患者接受了环孢素治疗，24例患者未接受该药物治疗。在这两组患者之间，识别TR的诊断敏感性（分别为0.86和0.80）和特异性（分别为0.93和0.84）并无显著差异。我们得出结论，在肾移植后的前两周，我们机构使用的环孢素治疗方案并不限制IPS作为TR检测方法的可靠性。
